A phase II, single-arm study of the anti-a5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.

A phase II, single-arm study of the anti-a5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011 May 01; 121(2):273-9.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Antibodies, Monoclonal
Biomarkers, Tumor
Drug Resistance, Neoplasm
Endothelial Cells
Female
Humans
Immunohistochemistry
Integrin alpha5beta1
Middle Aged
Neoplasms, Glandular and Epithelial
Neoplastic Cells, Circulating
Organoplatinum Compounds
Ovarian Neoplasms
Peritoneal Neoplasms
Stem Cells

authors with profiles

Ernst Robert Lengyel